CY1118275T1 - Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων - Google Patents

Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Info

Publication number
CY1118275T1
CY1118275T1 CY20161101091T CY161101091T CY1118275T1 CY 1118275 T1 CY1118275 T1 CY 1118275T1 CY 20161101091 T CY20161101091 T CY 20161101091T CY 161101091 T CY161101091 T CY 161101091T CY 1118275 T1 CY1118275 T1 CY 1118275T1
Authority
CY
Cyprus
Prior art keywords
glucocorticoids
glucocorticoid
relates
component
designed
Prior art date
Application number
CY20161101091T
Other languages
Greek (el)
English (en)
Inventor
Stanko Skrtic
Jörgen Johnsson
Hans Lennernäs
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of CY1118275T1 publication Critical patent/CY1118275T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CY20161101091T 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων CY1118275T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
CY1118275T1 true CY1118275T1 (el) 2017-06-28

Family

ID=35197481

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101091T CY1118275T1 (el) 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
CY20211100191T CY1124074T1 (el) 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100191T CY1124074T1 (el) 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Country Status (25)

Country Link
US (3) US8425937B2 (enExample)
EP (2) EP1744730B1 (enExample)
JP (2) JP5149618B2 (enExample)
CN (2) CN1942176B (enExample)
AU (1) AU2005235370B2 (enExample)
BR (1) BRPI0510044B8 (enExample)
CA (1) CA2564000C (enExample)
CY (2) CY1118275T1 (enExample)
DK (2) DK3072507T3 (enExample)
ES (2) ES2600556T3 (enExample)
HR (2) HRP20161380T1 (enExample)
HU (2) HUE030546T2 (enExample)
IL (2) IL178776A (enExample)
LT (2) LT3072507T (enExample)
ME (1) ME02584B (enExample)
MX (2) MXPA06012011A (enExample)
NZ (1) NZ585340A (enExample)
PL (2) PL3072507T3 (enExample)
PT (2) PT3072507T (enExample)
RS (2) RS61501B1 (enExample)
SE (1) SE0401031D0 (enExample)
SG (1) SG188081A1 (enExample)
SI (1) SI3072507T1 (enExample)
WO (1) WO2005102271A2 (enExample)
ZA (1) ZA200609680B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
PL1744760T3 (pl) * 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
EP1971312A1 (en) * 2005-12-06 2008-09-24 MonoSol Rx LLC Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) * 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
HUE056810T2 (hu) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Szív- és érrendszeri események kezelése és megelõzése kolchicin alkalmazásával
HRP20210963T1 (hr) * 2013-04-16 2021-09-17 Murray & Poole Enterprises, Ltd. Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
EP2886108B2 (de) 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
ES2906778T3 (es) * 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
PT745382E (pt) * 1994-01-31 2004-04-30 Yamanouchi Pharma Co Ltd Forma moldada por compressao com solubilidade intra-oral e processo para a sua producao
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
EP1368000A4 (en) 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PL372290A1 (en) 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
PL1744760T3 (pl) 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.

Also Published As

Publication number Publication date
MXPA06012011A (es) 2007-04-16
AU2005235370B2 (en) 2011-06-09
US20080187586A1 (en) 2008-08-07
EP1744730A2 (en) 2007-01-24
JP5681679B2 (ja) 2015-03-11
BRPI0510044A (pt) 2007-10-16
JP2007533698A (ja) 2007-11-22
ES2857600T3 (es) 2021-09-29
WO2005102271A2 (en) 2005-11-03
SG188081A1 (en) 2013-03-28
US8425937B2 (en) 2013-04-23
MX344197B (es) 2016-12-08
AU2005235370A1 (en) 2005-11-03
CN103006592B (zh) 2016-03-02
ME02584B (me) 2017-06-20
JP2012236846A (ja) 2012-12-06
HRP20210348T1 (hr) 2021-04-16
IL227375A (en) 2017-08-31
BRPI0510044B1 (pt) 2019-01-29
HRP20161380T1 (hr) 2016-12-02
IL178776A0 (en) 2007-02-11
DK3072507T3 (da) 2021-02-08
HK1179525A1 (zh) 2013-10-04
BRPI0510044B8 (pt) 2021-05-25
HUE053248T2 (hu) 2021-06-28
EP3072507A1 (en) 2016-09-28
WO2005102271A3 (en) 2006-08-03
CN103006592A (zh) 2013-04-03
CY1124074T1 (el) 2022-03-24
PT3072507T (pt) 2021-02-23
HUE030546T2 (en) 2017-05-29
EP3072507B1 (en) 2020-12-23
PL1744730T3 (pl) 2017-01-31
PT1744730T (pt) 2016-10-07
LT3072507T (lt) 2021-02-25
EP1744730B1 (en) 2016-08-03
ZA200609680B (en) 2008-08-27
NZ585340A (en) 2012-04-27
RS61501B1 (sr) 2021-03-31
CN1942176A (zh) 2007-04-04
US10583146B2 (en) 2020-03-10
RS55198B1 (sr) 2017-01-31
CA2564000A1 (en) 2005-11-03
SI3072507T1 (sl) 2021-04-30
DK1744730T3 (en) 2016-08-29
CA2564000C (en) 2013-07-02
CN1942176B (zh) 2013-09-18
US20140242167A1 (en) 2014-08-28
LT1744730T (lt) 2016-10-25
US20130129823A1 (en) 2013-05-23
IL178776A (en) 2013-10-31
JP5149618B2 (ja) 2013-02-20
PL3072507T3 (pl) 2021-07-19
ES2600556T3 (es) 2017-02-09
SE0401031D0 (sv) 2004-04-22

Similar Documents

Publication Publication Date Title
CY1118275T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
BRPI0410348A (pt) compostos e usos dos mesmos na modulação de amilóide-beta
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
BRPI0918611B8 (pt) composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
CY1119317T1 (el) Συνθεση για τοπικη εφαρμογη, χρησεις αυτης, συσκευη εφαρμογης και kit μερων
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão